Positive Interim Results from Phase 1/2 Clinical Study with ALN-CC5 for the Treatment of Complement-Mediated Diseases

Positive Interim Results from Phase 1/2 Clinical Study with ALN-CC5 for the Treatment of Complement-Mediated Diseases

We reported new data from our ongoing Phase 1/2 clinical study with ALN-CC5, an investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. Data were presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held December 5 – 8, 2015.  Results showed that administration of ALN-CC5 achieved up to 99% knockdown of serum C5 and up to 98% inhibition of serum hemolytic activity, an assay for complement activity.  Further, ALN-CC5 administration resulted in low levels of residual C5, which – based on comparisons from separate studies – were at or below the estimated levels of free C5 observed at therapeutic doses of eculizumab, an approved anti-C5 monoclonal antibody. The effects were also found to be highly durable, with C5 knockdown and complement inhibition results supporting a once monthly and possibly a once quarterly subcutaneous dose regimen.  Importantly, ALN-CC5 was shown to be generally well tolerated, with no clinically significant, drug-related adverse events to date.




We are encouraged by these results as we strive to improve the lives of patients with complement-mediated diseases. We believe that ALN-CC5 has the potential to offer a novel therapeutic option for these patients and their caregivers.



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.